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Abstract
One of the most significant barriers to medication treatment is patients’
non-adherence to a prescribed medication regimen. The extent of the impact
of poor adherence on resulting health measures is often unknown, and typical
analyses ignore the time-varying nature of adherence. This paper develops
a modeling framework for longitudinally recorded health measures modeled
as a function of time-varying medication adherence or other time-varying co-
variates. Our framework, which relies on normal Bayesian dynamic linear
models (DLMs), accounts for time-varying covariates such as adherence and
non-dynamic covariates such as baseline health characteristics. Given the in-
efficiencies using standard inferential procedures for DLMs associated with in-
frequent and irregularly recorded response data, we develop an approach that
relies on factoring the posterior density into a product of two terms; a marginal
posterior density for the non-dynamic parameters, and a multivariate normal
posterior density of the dynamic parameters conditional on the non-dynamic
ones. This factorization leads to a two-stage process for inference in which
the non-dynamic parameters can be inferred separately from the time-varying
parameters. We demonstrate the application of this model to the time-varying
effect of anti-hypertensive medication on blood pressure levels from a cohort
of patients diagnosed with hypertension. Our model results are compared to
ones in which adherence is incorporated through non-dynamic summaries.
∗Work supported by NIH grant R21 HL121366
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1 Introduction
Over 85 million American adults, or about one third of the population over 20 years
old, suffer from hypertension (Benjamin et al., 2018). Approximately 16% of adults
in the United States are unaware that they have hypertension (Benjamin et al.,
2018). Left untreated, hypertension can lead to a range of serious and costly health
concerns such as cardiovascular disease, stroke, and renal disease (Amery et al., 1985;
Probstfield, 1991). Among the many factors associated with uncontrolled BP, poor
adherence to prescribed anti-hypertensive medications is of increasing concern to
clinicians, health care systems, and other stakeholders (Choo et al., 1999; Morisky
et al., 1986; Osterberg and Blaschke, 2005). Little doubt exists that patients who ad-
here poorly to their prescribed medication are at risk for worse BP outcomes. Given
the large variation in adherence, both across patients and temporally within patients,
it is an open question how to accurately measure the impact of varying adherence
patterns on BP levels. Furthermore, the variation in adherence patterns creates
difficulties in accurately measuring the effects of socio-demographic and health risk
factors on BP levels.
This paper develops a Bayesian dynamic linear model (Durbin and Koopman,
2001; West and Harrison, 1997; Petris et al., 2009) for health measures recorded
over time as a function of time-varying adherence, with a particular application to
the effects of anti-hypertensive medication on BP levels. Bayesian dynamic linear
models (DLMs) have a long history as a statistical framework for forecasting and
measuring trajectories in many domains, including real-time missile tracking and
financial securities forecasting, but rarely in the health context. We apply DLMs to
describe time-varying health measures (like blood pressure levels) as a function of
detailed adherence (or other time-varying covariates) and individual demographics
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and comorbidities measured typically at study baseline. The application of DLMs to
the time-varying adherence on health measures is novel, but fits naturally into the
DLM framework because these measures can be “tracked” over time as adherence
data accumulate. Because the DLM framework permits the inclusion of patient-level
predictors, the model can be applied to measuring effects of socio-economic or racial
disparities, or the effects of different comorbid conditions. In these settings, our
model can control for differential medication adherence patterns, resulting in more
accurate measurement of the effects of other covariates.
Data for studies in which the estimated effects of time-varying adherence on
health measures are desired usually consist of three components. First, adherence
data for each study participant are assumed to be collected through electronic mon-
itoring devices. These devices electronically time-stamp each time the pill container
is opened, and permit an accurate recording of when a patient took their medication.
Second, health and socio-demographic are typically recorded at the start of medica-
tion adherence studies, and are often non-dynamic. Finally, health measures which
might be impacted by differential medication adherence are recorded over time at
intermittent intervals. Such measures are often recorded at clinic visits, the timing
of which may be determined by the patient. Thus it is quite common for the number
of health measures per study patient to be much fewer than the number of days in
which medication adherence information is recorded.
The DLM framework is challenged by having much fewer days with health mea-
sures compared to the number of days of adherence measurements. In typical uses
of DLMs, both time-varying covariates and responses are measured at every time
point, and inference for the time-varying state parameters can be accomplished us-
ing standard Bayesian updating algorithms (West and Harrison, 1997, Chapter 16).
With adherence data, when the responses are measured at irregular and infrequent
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intervals, the usual updating approaches can be demonstrably inefficient. Instead, we
develop an inferential approach in a Bayesian setting that takes advantage of factor-
ing the posterior density into a product of two terms. The first term involves the exact
marginal likelihood of the DLM, marginalizing out the dynamic state process. The
second is the conditional posterior density for the state process parameters. These
together allow us to determine the posterior distribution for the non-dynamic param-
eters using standard Markov chain Monte Carlo (MCMC) techniques as a first stage
and the state process parameters as a second stage without resorting to needlessly
complex computational tools. With a DLM that has normally distributed responses
and a stochastic process for the latent states the has normal innovations, the factor-
ization is the product of two multivariate normal densities. This factored posterior
density also easily permits inference for the non-dynamic parameters, which in the
setting of medication adherence is likely of interest because the researcher may want
to understand the effect of baseline health characteristics on the health measures
controlling for differential adherence.
The remainder of this paper is organized as follows. In Section 2 we introduce
a motivating example and details of the study cohort. We specify the DLM for our
framework in Section 3. The model, which assumes an autoregressive structure, ac-
counts for possibly multivariate health measures which may or may not be measured
simultaneously. We then develop our computational approach for inference in Sec-
tion 4. We apply our methods to modeling BP in Section 5 where we compare our
methods to typical models used to measure the effects of adherence. We conclude
in Section 6 with a discussion on the limitations and potential extensions of our
methods.
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2 Data
The data we analyzed were obtained from the baseline pre-randomization period of a
trial that studied the effects of a provider-patient communication skill-building inter-
vention on adherence to anti-hypertensive medication and on BP control (clinicaltri-
als.gov ID: NCT00201149). Patients were recruited from seven outpatient primary
care clinics at Boston Medical Center, an inner-city safety-net hospital affiliated with
the Boston University School of Medicine. Patients enrolled into the study from Au-
gust 2004 and June 2006, meeting several eligibility criteria. These included that the
patients were of white or black race (African or Caribbean descent), were at least 21
years old, had an outpatient diagnosis of hypertension on at least three different occa-
sions prior to study enrollment, and were currently on anti-hypertensive medication.
The cohort size was 869 patients. The study involved measuring anti-hypertensive
medication-taking using Medication Event Monitoring System (MEMS) caps, a par-
ticular type of electronic pill-top monitoring device. Patients were given their most
frequently taken anti-hypertensive medications in a bottle with a MEMS cap, and
were instructed to open the bottle each time they took a dose. Each MEMS cap
contained a microprocessor that recorded the date and time whenever the bottle was
opened, and the timing information was then downloaded through a wireless receiver
after the patient returned the MEMS cap. Our study focused on medication-taking
behavior during the entire pre-randomization baseline period of the study. A patient
was considered adherent to the prescribed medication on a day if the MEMS cap
was opened as many times as the daily medication dosing frequency, and not adher-
ent otherwise. These measurements were recoded on a daily basis, but the duration
over which adherence information was measured varied by patient. Blood pressure
measurements were recorded less frequently as they were obtained as part of routine
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clinical care.
The BP readings were assessed using manual or electronic devices, and were
obtained by clinical staff including physicians, nurses and medical assistants. In
cases where multiple readings were obtained on a single day (typically at the same
clinic visit), the individual values were recorded. Diastolic and systolic blood pressure
values (DBP and SBP respectively) were recorded separately.
In addition to detailed time-varying adherence and BP readings, other patient-
specific baseline information was collected. Race (white versus African American),
gender, income, and age at the start of the study were recorded for each patient. From
electronic medical records, the following comorbidities (as binary variables) were
investigated in our study, given their potential impact on overall BP levels: Presence
of cerebrovascular disease, congestive heart failure, chronic kidney disease, coronary
artery disease, diabetes mellitus, hyperlipidemia, peripheral vascular disease, and
obesity (defined as body mass index greater than 30kg/m2).
To motivate our modeling framework, consider the data from one of the patients in
the study cohort displayed in Figure 1. The figure shows the DBP and SBP measures
on the three days the patient had their blood pressure measured, and daily indications
of whether the patient was adherent. This patient was adherent for a total of 29 of 82
days. However, this simple summary masks the time-varying pattern of the patient’s
adherence. The patient began the study by being fully adherent to their prescribed
medication, during which time their blood pressure remained under control. After
20 days, the patient started becoming less adherent, and starting around day 38 the
patient discontinued taking their medication altogether. Over this latter period, the
patient’s BP increased, and by the end of the study period the patient has DBP and
SBP values that were not under control. Besides suggesting a potential link between
adherence and BP measures, this example motivates a dynamic linear model for
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Figure 1: Example BP and adherence data for a study patient. Red squares are
diastolic BP, red dots are systolic BP, and the black dots near the horizontal axis
indicate whether the patient was adherent on a particular day (filled dots indicate
adherence, open dots indicate non-adherence).
health measures that accounts for time-varying adherence.
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3 A dynamic model for multivariate health mea-
sures
We propose a statistical framework for multivariate time-varying health measures as a
function of medication adherence that is a member of the class of Bayesian dynamic
linear models. Let yitk be the value of the k
th health measure, k = 1, . . . , K, for
patient i at time t, t = 1, . . . , Ti. We assume that time is discretized and equally
spaced (e.g., days), and that health measures are observed only at times t1, t2, . . . , tmi .
Let yit·, generally, indicate a vector collecting all outcomes across the dotted index
into a column vector. In this example we collect the outcomes for patient i at time t,
i.e., yit· = (yit1, ...,yitK)T . Similarly, yi·k collects the kth outcome observed at times
(t1, ..., tmi) for patient i, i.e., yi·k = (yit1k, ...,yitmk)
T . Our framework assumes that
yit· is an observed measurement generated from a distribution with mean µit· which
follows a stochastic process. The framework recognizes that actual measurements
on a given day could vary around a mean level due to various influences including
emotional state, activity level, recent alcohol consumption, ambient temperature,
and other unobserved factors that might affect the outcomes.
The mean process at time t is modeled as the sum of the contributions of a
non-dynamic term and a stochastic term. Specifically, we assume
yit· = µit· + εit
= βxi +αit· + εit (1)
where xi is a vector of p non-dynamic covariates typically measured at baseline
and β are the corresponding linear coefficients, and where αit· is a stochastic pro-
cess that may depend on dynamic covariates, such as time-varying adherence. Here
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yit·,µit·,αit· and εit are all vectors of length K corresponding to the observation,
mean outcome process, latent state model and sampling error respectively. The non-
dynamic covariate effects β are of dimension K × p. We use βk to denote the kth
row of β, i.e., the non-dynamic covariate effects on the kth outcome. The error term
for subject i at time t, εit, accounts for typical sampling variability, measurement
error and possible correlation of the outcomes within patient and time. We further
assume that εit ∼ N(0, Σε) with possibly non-diagonal covariance matrix Σε.
If patient i’s adherence is tracked for Ti consecutive days, we indicate this mea-
surement set as {1, ..., Ti}, and denote the collection of time-varying adherence mea-
sures as {cit}Tit=1. We let cit = 1 if patient i was adherent on day t and −1 otherwise.
As we describe below, we extend the definition of cit to include other time-varying co-
variates. We further let Ti = {t1, ..., tmi} ⊂ {1, 2, ..., Ti} denote the set of mi days on
which the outcomes were measured for patient i. The set of outcome measurements
for patient i is denoted by yi·· = {yit·}t∈Ti . Crucially, we assume that mi << Ti for
all i.
Changes in αit· are assumed to be reflected by whether a patient takes the pre-
scribed medication along with any other time-varying covariates. We assume an
AR(1) model on the latent states {αit·} and incorporate the cit· as time-varying
covariates. Other forms of stochastic processes are possible, including autoregressive
processes of higher order. More generally, if cit· is of dimension r, then we assume a
process on αit· given by
αit· = ραi,t−1,· + φcit· + νit (2)
where ρ is the K-dimensional diagonal matrix of first-order autoregressive param-
eters, that is, ρ = diag(ρ1, ρ2, ..., ρK). We assume |ρk| < 1 to ensure stationar-
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ity. The time-varying outcome effects φ is a K × r matrix. We let φk denote
the kth row of φ, i.e., the time-varying covariate effects on the kth outcome. We
further assume in (2) that the innovations νit have zero-mean MVN distributions
with diagonal covariance matrix Σν = diag(σ
2
ν1, σ
2
ν1, ..., σ
2
νK). Similarly we assume
αi1 ∼ NK(0,Σ0) with Σ0 = diag(σ201, σ201, ..., σ20K). Let θ denote the non-dynamic
parameters θ = (β,Σε,ρ,φ,Σν ,Σ0). Equations (1) and (2) define the distributions
p(yit·|αit·,xi, θ) and p(αit·|αi,t−1,·, θ, cit·) respectively.
Figure 2 contains a simulated example of a patient with a scalar outcome over a
30-day period corresponding to the model in (1) and (2). The bottom of the figure
displays the adherence indicator simulated independently with a 90% probability of
adherence. The adherence effect is simulated to be large and negative (φ = −0.5).
The contribution of the non-dynamic covariates is assumed to be xTi β = 130.
As evidenced in Figure 2, the mean process generally declines on days when a
patient is adherent. This is not always the case, and an increase can occur when the
corresponding innovation νt is large and positive offsetting the impact of the patient
taking their medication. The observed health measure is normally distributed around
the mean for the day on which the measure is recorded. On day 1, for example, the
health measure is higher than the mean, and on day 15 the health measure is lower
than the mean.
This model is attractive for relating health measures to time-varying adherence for
several reasons. First, the model can account for non-dynamic baseline variables as
well as time-varying adherence. This model feature permits disentangling the effects
of detailed adherence from patient-specific socio-demographic and health covariates.
Second, in settings where multiple outcome measures are observed at time t, inference
for the sampling variability Σε can be made more precise, and help to separate from
the innovation variability Σν .
10
0 5 10 15 20 25 30
12
0
12
5
13
0
t
y
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l
ν1
ε1
ε15
ϕ c15 + ν15
µ1
µ14
µ15
y1
y15
xT β
l
l
Observed BP : yt
Latent BP : µt
l
l
ct = 1
ct = − 1
Figure 2: A 30-day trajectory for a simulated patient from a DLM with a scalar
outcome.
The assumption of an AR(1) model component has a well-known asymptotic
mean under full adherence and full non-adherence. Specifically, the overall effect of
repeated days of adherence on the outcome measure converges for increasing values
of t as αit· → (I−ρ)−1φ. We can therefore predict that if patient i were to continue
to be fully adherent, their mean outcomes would tend to µit· → βxi + (I − ρ)−1φ.
An analogous calculation can be performed when the patient is fully non-adherent.
This property permits estimating the best-case or worst-case health measure means
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for perfect adherence or perfect non-adherence, even when patients’ adherence level
is somewhere in between.
4 Marginal Dynamic Linear Models
Inference for the model in Section 3 is challenging given the large number of param-
eters, both the non-dynamic parameters θ as well as the time-varying parameters
α. In particular, if the number of recorded adherence indicators per patient is large,
then the size of α is similarly large. Standard Bayesian inferential methods through
posterior simulation approaches for such a highly parameterized model can result in
slow convergence and unreliable inferences.
Advances in Bayesian computation have made highly parameterized dynamic
models more tractable. With recent developments in sequential Monte-Carlo (SMC)
with software packages like Libbi (Murray, 2013), sampling the induced high-dimensional
latent states of the DLM has become computationally feasible and accessible. The
majority of these advances are in situations where the likelihoods can not be com-
puted directly and are instead approximated. Marginal sampling schemes, like the
particle marginal Metropolis-Hastings (PMMH) algorithm (Andrieu et al., 2010),
alternately sample the structural parameters and latent process parameters and ac-
cept or reject them with an adjusted Metropolis-Hastings step accounting for the
approximation of the likelihood needed in sampling the latent space. Recent work
(Bhattacharya and Wilson, 2018) approximates the posterior of the structural pa-
rameters on a grid of points, reducing the possible sampling values to a discrete
set. SMC has also been adapted to this situation in methods like SMC2 (Chopin
et al., 2012), or more aptly named Particle SMC, where one can exploit the known
sequential structure of otherwise intractable likelihoods.
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Our approach takes advantage of factoring the joint posterior density of θ and α
as follows
p(α, θ|y) = p(θ|y)p(α|θ,y). (3)
where we omit the dependence on both {cit} and xi. The first factor in (3) is
discussed below, while the second factor, the conditional posterior density of the
latent process parameters, can be derived exactly and is discussed in Section 4.2.
Marginal inference about θ can be accomplished by integrating (3) with respect
to α, yielding the first factor in the expression. This factor can be expanded using
Bayes’ Theorem as
p(θ|y) = p(y|θ)p(θ)
p(y)
. (4)
The marginal likelihood, p(y|θ), in the numerator is determined from
p(y|θ) =
∫
p(y,α|θ)dα. (5)
As we derive in Section 4.1, the marginal distribution in (5) is multivariate normal
(MVN) with a mean and variance that depend only on the fixed model parameters θ,
the adherence measures {cit} and individual covariates xi. This marginalization is
made possible by normality of the latent state innovations νit and sampling error εit.
Inference for θ can therefore be obtained directly from this marginal distribution.
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4.1 Marginal Likelihood of the DLM
We explain our marginalization approach in the case of a DLM with a single out-
come variable (k = 1) and for one individual, and assume a single baseline covariate
(p = 1) and single time-varying covariate (r = 1) which is assumed to be an ad-
herence indicator. The parameters in θ are therefore (β, σ2ε , ρ, φ, σ
2
ν , σ
2
0). We assume
that both adherence indicators and time-varying outcomes are measured over T
consecutive days; the outcomes are (y1, y2, ..., yT ) and the adherence indicators are
c = (c1, c2, ..., cT ). We can write the vector of outcomes as the sum of a shared
non-time-varying component, a time-varying component and an error term as
y1
y2
...
yT
 =

βx
βx
...
βx
+

α1
α2
...
αT
+

ε1
ε2
...
εT
 = βx 1T +α+ ε. (6)
where we use the 1T notation to indicate a column vector of length T consisting of
all ones. The following development is conditional on θ and covariates (x, c) unless
noted otherwise. Thus the first term on the right hand side of Equation (6), βx 1T ,
is treated as a constant vector. The third term is distributed as
ε ∼ NT (0, σ2εI),
where 0 is a column vector of zeros, and I is a T -dimensional identity matrix.
Because the initial latent variable α1 is normally distributed, and each αt con-
ditional on the previous latent variables is a linear combination of normal random
variables, then (α1, ..., αT ) is MVN.
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The AR(1) structure of the latent states admit a recursive mean and variance
calculation
E[αt] = ρE[αt−1] + φ ct,
Var[αt] = ρ2Var[αt−1] + σ2ν .
This recursion and the initial conditions imply a general formula for the mean and
variance of αt
Et = E[αt] = φ
t∑
k=2
ρt−kck (7)
Vt = Var[αt] = σ2ν
t∑
k=2
ρ2(t−k) + ρ2(t−1)σ20
for t ∈ {2, ..., T} with initial mean E1 = E[α1] = 0 and initial variance V1 =
Var[α1] = σ20. We collect the mean terms into a vector
E = (E1, ..., ET ). (8)
The covariance follows a similar recursion,
Cov(αt, αt−1) = Cov(ραt−1 + φ ct + νt , αt−1)
= ρ Var[αt−1].
We apply the recursion to obtain a general form of the covariance for t ∈ {2, ..., T}
and k ∈ {0, ..., t− 1}
Cov(αt, αt−k) = ρkVar[αt−k] = ρkVt−k.
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More compactly, the covariance matrix is
Σ =

V1 ρ V1 ρ
2 V1 . . . ρ
T−1 V1
ρ V1 V2 ρ V2 . . . ρ
T−2 V2
ρ2 V1 ρ V2 V3 . . . ρ
T−3 V3
...
...
...
. . .
...
ρT−1 V1 ρT−2 V2 ρT−3 V3 . . . VT

. (9)
The distribution of the terms in Equation (6) can be written explicitly as
(y1, y2, ..., yT )
T ∼ NT (βx 1T + E,Σ + σ2εI). (10)
The distribution in (10) is proportional to the marginal likelihood for T sequentially-
observed outcomes, marginalizing out the latent parameters.
Let T = {t1, t2, ..., tm} be the actual observation times, and let
ET = (Et1 , Et2 , ..., Etm)
T .
By properties of the MVN distribution, the outcome vector y· = (yt1 , yt2 , ..., ytm)
T is
also MVN with mean and covariance respectively
E[y·] = βx 1|T | +ET
Var[y·] = ΣT ×T + σ2εI|T |. (11)
The notation ΣT ×T indicates subsetting the covariance matrix Σ to the corresponding
rows and columns designated by T . If, for example, T = {1, 7, 9} the first, seventh
and ninth rows and columns are taken from Σ making ΣT ×T a 3 × 3 matrix. One
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consequence of the marginalization is that if we observe multiple measurements of
the same outcome on a single day, they will only vary according to σ2ε .
It is worth noting that even though this marginal distribution does not depend on
the time-varying parameters, the autoregressive structure remains in both the mean
and covariance. For example, the centered marginal mean of yt can be shown with
simple algebraic manipulation to be
(E[yt]− βx) = ρ (E[yt−1]− βx) + φct.
This is the same recursive relationship of the dynamic component of our DLM in (2).
Even though we marginalize out the time-varying parameters, their sequential struc-
ture is retained.
The calculations above were derived for one study participant and a single out-
come variable. These calculations can also be extended to multivariate outcome mea-
surements. The marginal mean and covariance are both individual- and outcome-
dependent, as both φk and αitk vary by outcome and individual. When referring to
multiple study participants and multiple outcome variables, we can make the depen-
dence explicit by denoting the quantities in (8) and (9) for outcome k of individual
i as Eik and Σik respectively.
Because the majority of the structure is contained within outcome (recall ρ
is a diagonal matrix), we organize the multivariate outcomes as follows. We col-
lect the outcome k observed through time t = 1, ..., Ti into a Ti × 1 vector yi·k =
(yi1k, yi2k, ..., yiTik)
T . The marginal likelihood of a vector of complete outcome mea-
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surements can be written as
yi·1
yi·2
...
yi·k
 | θ ∼ NkT (Ei + βxi ⊗ 1Ti , Σi + Σε ⊗ ITi) (12)
where ⊗ is the Kronecker product, and where
Ei =

Ei1
Ei2
...
Eik
 and Σi =

Σi1 0 · · · 0
0 Σi2 · · · 0
...
...
. . .
...
0 0 · · · Σik
 . (13)
As in (11), we can derive the marginal distribution of the outcome measures yi··|θ
by subsetting the appropriate rows and columns of the quantities in (13).
If we assume that outcomes between study participants are independent condi-
tional on θ, the marginal distribution of outcomes unconditional on the time-varying
parameters is given by
p (y1··, ...,yn··|θ,x, c) =
n∏
i=1
p (yi··|θ, xi, ci··) . (14)
This simple marginalization drastically reduces the number of parameters in the
model and simplifies computation. We can conduct inference on our non-dynamic
parameters in a Bayesian setting by introducing a prior distribution for θ and using
the marginal likelihood of θ which is proportional to (14). The posterior density for
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the non-dynamic parameters is given by
p (θ| {yi··}ni=1 ,x, c) ∝ p(θ)
n∏
i=1
p (yi··|θ, xi, ci) . (15)
Inference can be performed in a straightforward and efficient way via MCMC, or us-
ing Hamiltonian Monte Carlo (Homan and Gelman, 2014) sampling to obtain draws
from the posterior distribution, as implemented in STAN (Carpenter et al., 2017).
Alternatively, posterior sampling could be obtained using Sequential Monte-carlo
(SMC) in software packages like Libbi (Murray, 2013). SMC works with the sequen-
tial likelihoods p(yitj |yit1 , ..., yitj−1 , θ), which are easily available in our framework
because they are conditional distributions of the Multivariate Normal distribution
in (12).
4.2 Inference for the Latent Process
Posterior inference for α can be determined once p(θ|y) has been obtained by ex-
ploiting the factorization of the posterior density in (3). To do so, we note that the
joint distribution of α and y conditional on θ is MVN. For our development, we
consider the case in which outcomes are observed for T consecutive days. With a
k-dimensional outcome variable, α contains kT elements and y contains kT (scalar)
outcomes. Using the notation in (13), the joint distribution of outcomes and time-
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varying parameters is
αi·1
...
αi·k
yi·1
...
yi·k

∣∣∣∣∣∣∣∣∣∣∣∣∣∣∣∣∣∣
θ ∼ N2kT


Ei
Ei + βxi ⊗ 1Ti
 ,

Σi Σi
Σi Σi + Σε ⊗ ITi

 . (16)
The quantities on the diagonal of the covariance matrix in (16) were determined in
Section 4.1. The covariance of yi·k and αi·` (for k 6= `), conditional on θ, can be
shown to be 0 as follows (with conditioning on θ suppressed).
Cov(αi·l,yi·k) = E [Cov (αi·l,yi·k|αi·k)] + Cov (E[αi·l|αi·k],E[yi·k|αi·k])
= E [Cov (αi·l, βxi +αi·k + εi·k|αi·k)] + Cov (αi·l, βxi +αi·k)
= E [Cov (αi·l, εi·k)] + Cov (αi·l,αi·k)
= 0.
We can subset the mean vector and covariance matrix of (16) as in (11) to account
for the sporadically observed outcomes, but we continue to assume that the response
values are observed at each time period. The conditional posterior distribution of the
latent parameters is determined from the joint distribution in (16) by conditioning
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on y as 
αi·1
...
αi·k

∣∣∣∣∣∣∣∣∣yi·1, ...,yi·K , θ ∼ NkT
(
α˜i, Σ˜i
)
(17)
where
α˜i = (Ei) + Σi (Σi + Σε ⊗ ITi)−1


yi·1
...
yi·k
− (Ei + βxi ⊗ 1Ti)

and
Σ˜i = Σi − Σi (Σi + Σε ⊗ ITi)−1 Σi.
We can use the joint distribution specified in (17) along with the posterior distribu-
tion on the structural parameters shown in (15) to sample from the latent process
parameters by first simulating θ∗ ∼ p (θ|y1··, ...,yn··,x, c) and then sampling from
p(αi·1, ...,αi·1|y1··, ...,yn··, θ∗).
5 Application to BP Study
We return to an application of our framework to modeling time-varying BP as a
function of time-varying adherence to anti-hypertensive medication and baseline co-
morbidities and demographics described in Section 2. We begin with a discussion of
models often used in this task that incorporate adherence as non-dynamic informa-
tion. We also address missing adherence measures for a fraction of patients.
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5.1 Non-dynamic models incorporating adherence
Adherence to medication is typically incorporated into outcome models in one of
two ways. The average adherence for the study period is either used directly or is
dichotomized into two groups, those below a certain threshold and those above, indi-
cating “poor” versus “good” adherence (Rose et al., 2011; Lee et al., 2006; Schroeder
et al., 2004). Either of these approaches includes adherence as a non-dynamic covari-
ate in the model. Repeated outcome measures are accompanied by patient-specific
random effects.
We present these alternative models in the context of BP outcomes, a bivariate
measure. We label the outcomes 1 for Systolic BP and 2 for Diastolic BP. These
models take the formyit1
yit2
 =
xiβ1
xiβ2
+
δi1
δi2
+
c¯iγ1
c¯iγ2
+
εit1
εit2
 (18)
with two different adherence measures, c¯i. We first consider average adherence,
c¯i = T
−1
i
∑Ti
t=1 cit over Ti days for patient i. In this case we would interpret the
adherence effect parameters (γ1, γ2) as the differences in BP of being fully adherent
relative to being fully non-adherent, controlling for the baseline covariates. We also
consider a dichotomized summary c¯i = 1
{(
T−1i
∑Ti
t=1 cit
)
> 2p− 1
}
, an indicator
of overall adherence. In this case (γ1, γ2) would be interpreted as the differences
in BP for those with “good” (c¯i = 1) versus “poor” (c¯i = 0) adherence. Several
values of p were considered to assess the sensitivity to this choice, but we present
results for p = 0.8 which is a conventional choice (Schroeder et al., 2004). The
model in Equation (18) includes patient-specific random effects δi1 ∼ N(0, σ2δ1) and
δi2 ∼ N(0, σ2δ2).
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We compare the fit of the above two non-dynamic models to our dynamic model
framework. The non-dynamic approach has a potential advantage of being more
robust to detailed model misspecification relative to our dynamic model, particularly
with the choice of the specific model for the evolution of the health measures as a
function of daily adherence. However, incorporating average adherence may mask
important time-varying effects of detailed adherence. We explore this tradeoff in
Section 5.3.
5.2 Missing adherence indicators
Not all of the patients in our cohort have completely observed adherence indicators.
Among the 503 patients in our analyses, 70 have at least one day of missing adherence.
Adherence could be missing due to MEMS cap malfunctions, hospital inpatient stays
in which the MEMS containers were not used, or other causes. The majority (50) of
the 70 patients had only one or two missing adherence values. In the most extreme
case one patient was missing 48 out of 102 adherence measures.
For patient i, let cobsi = {cit}t∈Tobs be the set of observed adherence values and
cmisi = {cit}t∈Tmis be the set of missing adherence values. Letting ηi represent the
parameters describing a potential adherence model for patient i, the posterior density
in (15) conditional on the observed adherence data only is
p
(
θ|yi··, xi, cobsi
)
=
∫
p
(
θ, cmisi , ηi|yi··, xi, cobsi
)
dcmisi dηi
=
∫
p
(
θ|yi··, xi, cobsi , cmisi , ηi
)
p
(
cmisi |yi··, xi, cobsi , ηi
)
p(ηi|yi··, xi, cobsi ) dcmisi dηi
(a)
=
∫
p
(
θ|yi··, xi, cobsi , cmisi , ηi
)
p
(
cmisi |ηi
)
p(ηi|cobsi ) dcmisi dηi. (19)
The last line in (19) labeled (a) involves a set of modeling choices. First, we as-
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sume that the adherence model parameters do not depend on other covariates or
the outcomes, and this is reflected by assuming p(ηi|yi··, xi, cobsi ) = p(ηi|cobsi ). Other
approaches, such as those described by Naranjo et al. (2013), provide a framework
for modeling missing time-varying covariates in DLMs with complex models. How-
ever, our assumption is conservative but likely more robust to model misspecification.
Second, p
(
cmisi |yi··, xi, cobsi , ηi
)
= p
(
cmisi |ηi
)
, implies that the missing adherence val-
ues can be simulated directly from our adherence model, represented by ηi, without
regard to individual-level characteristics. Again, this is a conservative choice be-
cause adding information to the imputation model could help improve predictions if
properly modeled.
We simulate the missing adherence measures from Beta-Bernoulli distributions
that depend only on adherence measures for each patient separately. Letting ηi
represent patient i’s overall adherence, the unobserved adherence values are drawn
from a Bernoulli distribution
{c∗it}t∈T |ηi i.i.d.∼ Bernoulli(ηi)
where the cit = 2c
∗
it − 1 take on values {−1, 1}. Under a uniform prior distribution
on patient i’s adherence rate, the posterior distribution for ηi is given by
ηi|{cit}t∈Tobs ∼ Beta(ni,1 + 1, ni,−1 + 1)
when they were observed to be adherent ni,1 days and non-adherent ni,−1 days.
We repeated the simulation process 20 times and combined the posterior samples
for a proper Bayesian multiple-imputation analysis (Little and Rubin, 2002) for our
non-dynamic models. For our fully Bayesian model, the simulated adherence values
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were incorporated into our posterior simulation analyses. We found that in both
cases inference of our non-dynamic parameters θ was not sensitive to the missing
adherence values.
5.3 Analysis of BP measures
Table 1 displays the number of BP measurements among our 503 patients during
the study period. While a majority (69.8%) had either one or two BP readings, a
substantial number of patients had 3 or more. The number of BP readings totalled
1152, averaging 2.29 readings per patient.
Number of BP Readings 1 2 3 4 5 6 7 8+
Number of Patients 226 125 72 28 16 12 15 9
Percent of Patients 44.90 24.90 14.30 5.60 3.20 2.40 3.00 1.79
Table 1: Number of BP readings during the study period.
For the period of the study, the proportion of days that patients took their med-
ication varied widely. The proportions ranged from 8.9% to 100%, with a median of
95.1% and a mean of 88.9%. These adherence rates on average were high, with many
patients being fully adherent throughout the study period. Only 19.1% of patients
had below 80% adherence. The high degree of adherence is consistent with recruiting
patients for the study who were continual users of anti-hypertensive medication. On
average, adherence was recorded over 98 days per patient (minimum and maximum
of 21 and 395 days, respectively, with an inter-quartile range of 14), with 75% of
patients followed between 84 and 112 days.
Baseline summaries of the non-dynamic covariates appear in Table 2. A majority
of the cohort consisted of women, more patients of black race (African or Caribbean
descent) than white, and a large fraction of low-income patients. The cohort also
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Mean (Std Dev)
Age (y) 60.3(11.1)
DBP at Enrollment 79.7(11.5)
SBP at Enrollment 133.5(19.6)
Percent
Female 67.5
African-American 54.9
Income below $20, 000 44.3
Obese 60.6
Cerebral Vascular Disease 5.6
Congestive Heart Failure 3.8
Renal Insufficiency 6.8
Coronary Artery Disease 14.9
Diabetes 36.2
Hyperlypidemia 57.1
Peripheral Vascular Disease 6.2
Table 2: Baseline socio-demographic and health characteristics of the patients in the
study cohort.
consisted of mostly obese patients, and had a moderately high comorbidity burden.
Based on 503 patients with BP readings within 14 days of enrollment, the cohort on
average had relatively well-controlled hypertension at baseline, as all patients were
prescribed anti-hypertensive medication (though adherent to varying extents). The
cohort consisted of 26.2% having DBP>80 mm Hg and SBP>130 mm Hg), and 7.8%
having DBP>90 mm Hg and SBP>140 mm Hg).
A prior distribution was assumed for the alternative models specified in (18). For
k = 1, 2, indicating systolic and diastolic BP measures separately, we assumed the
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following.
ρk ∼ U(−1, 1)
φk ∼ N(0, 25)
γk ∼ N(0, 25)
σεk ∼ U(0, 30), ρε ∼ U(−1, 1)
σνk ∼ U(0, 10), σ0k ∼ U(0, 30)
β11 ∼ N(120, 400), β12 ∼ N(80, 400)
βjk ∼ N(0, 400), j = 2, ..., p
σUk ∼ U(0, 30)
The prior components were selected to be vague but proper. The intercepts β1k had
distributions centered near the typical systolic and diastolic BPs, but had variances
that were sufficiently large to acknowledge the uncertainty in the effects. We assumed
uniform prior components with compact support for the standard deviation parame-
ters, as recommended by Gelman et al. (2006). The correlation and autocorrelation
parameters were assumed to have uniform prior components as in the dynamic model
parametrization. Convergence of the MCMC simulated values was inspected with
trace plots of multiple chains, and using the Gelman-Rubin convergence statistic
(Gelman and Rubin, 1992).
Table 3 presents posterior means and 90% central posterior intervals for the non-
dynamic covariate effects using the DLM. The point estimates and intervals are
reported for the DLM only; the effects in the alternative models that were significant
at the 0.1 level are indicated with a † (for the average adherence model) or a ‡ (for
the dichotomized adherence model). Effects with 90% central posterior intervals not
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Variable Systolic (90% CI) Diastolic (90% CI)
Intercept 132.97 (129.46, 136.51)?†‡ 85.68 (83.65, 87.72)?†‡
Sex (male) −1.1 (−3.59, 1.38) 0.53 (−0.88, 1.94)
Age (group 1) −0.01 (−3.3, 3.27) −1.5 (−3.4, 0.4)
Age (group 2) 1.87 (−1.45, 5.19) −3.54 (−5.45,−1.63)?†‡
Age (group 3) 5.22 (1.57, 8.89)?†‡ −6.73 (−8.83,−4.62)?†‡
White −3.31 (−5.61,−1.01)?†‡ −1.58 (−2.88,−0.26)?
Obese 3.07 (0.76, 5.38)?†‡ 1.68 (0.35, 3.01)?†‡
Nicotine dependence −0.9 (−5.22, 3.42) 1.3 (−1.17, 3.76)
Hyperlipidemia −1.44 (−3.71, 0.83) −1.34 (−2.64,−0.04)?
Diabetes 1.44 (−0.96, 3.85) −2.98 (−4.34,−1.61)?†‡
Peripheral vascular disease −1.28 (−5.75, 3.17) −2.6 (−5.13,−0.06)?†
Renal insufficiency −0.67 (−4.88, 3.52) −2.73 (−5.14,−0.33)?†‡
Benign prostatic hypertrophy 2.82 (−3.66, 9.3) −1.59 (−5.34, 2.15)
Coronary artery disease −1.66 (−4.77, 1.45) −2.76 (−4.54,−0.98)?†‡
Congestive heart failure −0.78 (−6.05, 4.46) 0.59 (−2.44, 3.59)
Cerebral vascular disease 2.45 (−2.19, 7.06) −0.17 (−2.82, 2.48)
Table 3: Summaries of covariate effects for the bivariate dynamic linear model.
?Effect with 90% posterior interval not containing 0 in DLM, †Significant effect
at the 0.1 level in average adherence model, ‡Significant effect at the 0.1 level in
dichotomized adherence model.
containing 0 marked with an asterisk (?). Based on the model fits, the estimated
covariate effects tend to be similar across all models with the point estimates tending
to agree in magnitude and sign. Even though the DLM covariate effects tended to
have narrower intervals on average (3% reduction), the significance of the findings
tended to agree as well. In particular, the effect of race (white versus non-white) was
significantly negative, indicating that whites tended to have lower blood pressure
controlling for all other variables and time-varying adherence. Patients who were
obese at the beginning of the study tended to have significantly higher DBP and SBP.
These findings are consistent with the results of previous studies (Kressin et al., 2010;
Rose et al., 2011) in their significance and direction of the effects. Both of these,
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except for the effect of being white on mean diastolic BP, agreed with the alternative
models in terms of significance and directionality of the effect.
Table 4 reports inferences for the standard error and correlations of (εit) for all
three models. Comparing the sampling standard deviation estimates across models
Dynamic linear model
Variable Systolic (90% CI) Diastolic (90% CI)
Standard Errors: 13.37 (12.46, 14.25) 8.11 (7.68, 8.54)
Correlation: 0.62 (0.57, 0.67)
Average Adherence Model
Variable Systolic (90% CI) Diastolic (90% CI)
Standard Errors: 14.53 (13.87, 15.21) 8.34 (7.97, 8.72)
Correlation: 0.58 (0.54, 0.62)
Dichotomized Adherence Model
Variable Systolic (90% CI) Diastolic (90% CI)
Standard Errors: 14.5 (13.86, 15.18) 8.34 (7.96, 8.72)
Correlation: 0.58 (0.54, 0.62)
Table 4: Measurement error estimates for three models.
provides an indication of the gains in modeling the adherence effects as time-varying.
The standard error estimates for the alternative adherence models tend to be slightly
larger than those given by the DLM, which is consistent with previous work (Rose
et al., 2011). The time-varying adherence explicitly captured in the DLM may ac-
count for the extra variation in the outcomes of the alternative adherence models
through a reduction in the estimated measurement error variance.
Table 5 contains the adherence effects for our models. The adherence effects
across the three models are not directly comparable, given the different approaches
to incorporate adherence. The average adherence model indicates that the differ-
ence between those who were fully adherent and those who were fully non-adherent,
controlling for other covariates, is about −9.2 and −9.5 for systolic and diastolic,
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State Space Model
Variable Systolic (90% CI) Diastolic (90% CI)
Adherence effect: -0.48 (-0.84, -0.2)? -0.24 (-0.43, -0.09)?
Asymptotic Adherence effect: -3.87 (-5.98, -1.83)? -3.15 (-4.38, -1.94)?
Alternative Adherence Model: Average Adherence
Variable Systolic (90% CI) Diastolic (90% CI)
Adherence effect: -9.24 (-16.03, -2.22)? -9.46 (-13.55, -5.52)?
Alternative Adherence Model: Dichotomized Adherence (p = 0.8)
Variable Systolic (90% CI) Diastolic (90% CI)
Adherence effect: -5.49 (-8.26, -2.75)? -3.78 (-5.27, -2.2)?
Table 5: Adherence effects for the models considered
respectively. This implies, for example, that a 10% additive increase in adherence
corresponds to a 0.92 and 0.95 reduction in systolic and diastolic blood pressure,
respectively. However, this effect size assumes that the relationship between average
adherence and blood pressure is linear and holds throughout the entire range of ad-
herence. Given the limited range of average adherence observed in the data (90% of
patients have average adherence above 70.5%), interpreting this effect beyond this
range is not recommended because it involves extrapolating beyond the data. The
dichotomized adherence model shows similar results. In particular this approach in-
volves comparing those with relatively good overall adherence (above 80% adherent)
to everyone else. Based on the dichotomized adherence model, the benefit of being
in the former group is indicated by a lower blood pressure of −5.49 and −3.78 on
average for systolic and diastolic blood pressure.
The DLM gives similar results. The effect of taking medication can be inferred
on a daily basis. The results of the model fit suggest a small but significant reduction
of blood-pressure from taking the medication on a daily basis, −0.24 mm Hg and
−0.12 mm Hg on average for systolic and diastolic BP, respectively. These estimates
imply that, accounting for the correlation estimate, a patient who is adherent over
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consecutive days would experience a long-term reduction in systolic BP by −3.9 mm
Hg, and a long-term reduction in diastolic BP by −3.15 mm Hg. The magnitudes
of an increase in long-term BP for continued non-adherence is the same but in the
opposite direction. Overall, the adherence effects tend to agree in terms of the
significance and direction for the different models. However, the DLM provides a
clearer interpretation of these parameters that is consistent with the time-varying
nature of the data.
Another benefit of the DLM is our ability to infer the latent BP for unobserved
days using the procedure discussed in Section 4.2. Figure 3 contains an example of
posterior draws of the mean process µit· = βxi + αit· for the patient presented in
Figure 1. The solid line indicates the posterior mean of the latent process while the
dashed lines indicate a 90% credible envelope across time. That is, for each time t,
a 90% credible interval of αit1,αit2| {yi··}ni=1 is shown. The estimated mean DBP
and SBP processes vary gradually over time, with shifts in direction indicated by
medication adherence variation.
6 Discussion
In this article we propose a multivariate DLM that can be used for modeling time-
varying outcome measures as a function of detailed medication adherence or other
time-varying covariates. While DLMs are of common use, our particular setting
benefits from a two-stage computational approach made possible by factorizing the
posterior density into the dynamic and non-dynamic parameters. Typical analyses in
this setting ignore the time-varying structure of medication adherence and instead
examine this relationship between adherence and outcomes via correlations with
non-dynamic adherence measures (e.g., time-averaged adherence). Our framework
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Figure 3: 90% central posterior intervals for the mean blood pressure {µit·} for one
study subject. The solid lines are the estimated mean DBP and SBP, and the dashed
lines are the point-wise posterior intervals. Horizontal dotted lines are drawn at the
baseline-estimated mean DBP and SBP.
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explicitly provides a measure of daily impact of medication-taking and meaningful
bounds for mean BP while controlling for baseline covariates.
Our modeling approach is sufficiently flexible to permit a wide range of assump-
tions distinct from those we included in our hypertension application. For example,
we assumed an AR(1) modeling structure for the mean outcome process, and this
assumption can be justified based on the pharmacokinetic properties of the medi-
cations. In other settings, alternative mean processes can be considered, including
higher order AR processes, growth curves, and so on. Our baseline covariates were
modeled linearly, but our framework permits non-linear inclusion of covariate infor-
mation for both baseline non-dynamic covariates, as well as the dynamic predictors
in the mean process component of our model. A crucial assumption of our framework
is that the outcome distribution is multivariate normal, as this assumption allows
for the marginalization strategy that leads to an efficient computational procedure.
However, with some non-normal outcome distributions, various strategies can be
employed that can potentially take advantage of the marginalization idea. For ex-
ample, non-normal outcome densities can be approximated by normal distributions
after which the marginalization can be performed; then a Metropolis-Hastings al-
gorithm would be incorporated into the posterior sampling procedure that would
account for the non-normality of the original sampling distribution. Such a proce-
dure is likely to be far more efficient than sampling the dynamic parameters directly
as part of model fitting.
The proposed modeling framework also permits extensions that are straightfor-
ward to incorporate. For example, multivariate outcomes that are recorded at stag-
gered intervals can be accommodated by marginalizing the distribution in (12) ap-
propriately. We may also believe that the effect of adherence to medication varies
from person to person. We can then include patient-specific adherence effects with a
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hierarchical prior on these parameters to share information across individuals. Our
analyses did not acknowledge differences among anti-hypertensive medications, but
our framework permits distinguishing differential medication effects in a natural man-
ner. The effects of different medications, perhaps grouped by relevant characteristics
such as whether the medication is short-acting or long-lasting, or by medication type
(e.g., for hypertension, diuretics, ACE inhibitors, etc.), can be included as separate
time-varying effects in the dynamic component of our model. Dosages and dosing
frequencies can serve as covariates for the effects of particular medications.
The framework we developed can help establish answers to questions of inter-
est to clinicians and medical researchers that have been difficult to assess through
simpler models. In particular, our model can establish the effects of different socio-
demographic or health factors on health outcomes that control for detailed time-
varying adherence to medication by recognizing that medication-taking behaviors
can change over time. From our framework, we can also estimate the daily im-
provement in being adherent to one’s medication, controlling for socio-demographic
and health characteristics, but also the likely long-range achievable mean outcomes.
We can also use the model to forecast health outcomes as a function of specified
patterns of adherence, potentially serving as a tool for medical decision-making by
clinicians. Our approach provides a robust framework for understanding the impacts
of poor medication adherence as clinicians and patients work together to improve
their medication treatment.
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